Summary for Factor VIII - von Willebrand Factor

  • Trade Names: Alphanate (Grifols); Haemate (CSL Behring); Opivate (BPL); Vonvendi
  • Indications: Control and prevention of bleeding in patients with hemophilia A; surgical procedures in patients with von Willebrand disease in whom desmopressin is either ineffective or contraindicated
  • Class: Antihemorrhagic, Coagulation factor VIII
  • Half-life: 12.4 hours
  • Clinically important, potentially hazardous interactions with:
    None known

Please login to view the rest of this drug profile.

Page last updated 08/20/2025

Symbol key

Incidence - Help

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness - Help

Hospitalization possible
Life threatening
Fatal

Warnings in other populations - Help

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric

Back to top